Repurposing of the antibiotic nitroxoline for the treatment of mpox
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28652 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Denisa Bojkova und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Virology, University Hospital, Goethe University, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Drug Repositioning, Mpox, Monkeypox, Nitroquinolines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The antiviral drugs tecovirimat, brincidofovir, and cidofovir are considered for mpox (monkeypox) treatment despite a lack of clinical evidence. Moreover, their use is affected by toxic side‐effects (brincidofovir, cidofovir), limited availability (tecovirimat), and potentially by resistance formation. Hence, additional, readily available drugs are needed. Here, therapeutic concentrations of nitroxoline, a hydroxyquinoline antibiotic with a favourable safety profile in humans, inhibited the replication of 12 mpox virus isolates from the current outbreak in primary cultures of human keratinocytes and fibroblasts and a skin explant model by interference with host cell signalling. Tecovirimat, but not nitroxoline, treatment resulted in rapid resistance development. Nitroxoline remained effective against the tecovirimat‐resistant strain and increased the anti‐mpox virus activity of tecovirimat and brincidofovir. Moreover, nitroxoline inhibited bacterial and viral pathogens that are often co‐transmitted with mpox. In conclusion, nitroxoline is a repurposing candidate for the treatment of mpox due to both antiviral and antimicrobial activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Virology, University Hospital, Goethe University, Frankfurt am Main, Germany.
- Department of Dermatology, Venereology and Allergology, University Hospital, Goethe University, Frankfurt am Main, Germany.
- Institute for Medical Microbiology and Infection Control, University Hospital, Goethe University, Frankfurt am Main, Germany.
- Institute of Virology, Charité-Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
- German Center for Infection Research (DZIF), Berlin, Germany.
- German Center for Infection Research, DZIF, External partner site, Frankfurt am Main, Germany.
ORCID-Profile: Martin Michaelis
Zitieren
APA
Bojkova, D., Zöller, N., Tietgen, M., Steinhorst, K., Bechtel, M., Rothenburger, T., Kandler, J. D., Schneider, J., Corman, V. M., Ciesek, S., Rabenau, H. F., Wass, M. N., Kippenberger, S., Göttig, S., Michaelis, M., & Cinatl, J. (2023). Repurposing of the antibiotic nitroxoline for the treatment of mpox. Journal of Medical Virology. https://doi.org/10.1002/jmv.28652
Vancouver
Bojkova D, Zöller N, Tietgen M, Steinhorst K, Bechtel M, Rothenburger T, et al. Repurposing of the antibiotic nitroxoline for the treatment of mpox. Journal of Medical Virology. 2023. doi:10.1002/jmv.28652
BibTeX
@article{Bojkova2023,
author = {Bojkova, Denisa and Zöller, Nadja and Tietgen, Manuela and Steinhorst, Katja and Bechtel, Marco and Rothenburger, Tamara and Kandler, Joshua D and Schneider, Julia and Corman, Victor M and Ciesek, Sandra and Rabenau, Holger F and Wass, Mark N and Kippenberger, Stefan and Göttig, Stephan and Michaelis, Martin and Cinatl, Jindrich},
title = {Repurposing of the antibiotic nitroxoline for the treatment of mpox},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28652}
}
EUVIMED